Diaccurate SAB has scooped a cancer drug from Germany’s Merck KGaA, transforming the small French biotech into a clinical-stage company. With expertise on its scientific advisory board from Nobel prize winner Tasuku Honjo, famously credited with the work establishing PD-1 as a target in immune-oncology, Diaccurate said it has fought off other competitors to acquire M-2698.